![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2007 Baroldi et al; licensee BioMed Central Ltd. Ultrasound Imaging Versus Morphopathology in Cardiovascular Diseases: The Heart Failure 1Institute of Clinical Physiology, National Research Council, Milan and Pisa, Italy 2Cardiology, University School of Medicine and Centro Diagnostico Italiano, Milan, Italy 3Cardiovascular Unit, "Campo di Marte" Hospital, Lucca, Italy Corresponding author.Giorgio Baroldi: riccardo.bigi/at/unimi.it; Riccardo Bigi: riccardo.bigi/at/unimi.it; Lauro Cortigiani: lacortig/at/tin.it Received November 30, 2006; Accepted January 30, 2007. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract This review article summarizes the results of histopathological studies to assess heart failure in humans. Different histopathological features underlying the clinical manifestations of heart failure are reviewed. In addition, the present role of echocardiographic techniques in assessing the failing heart is briefly summarized. Review Any cardiac disease may end in congestive heart failure (CHF), including coronary heart disease. Since mortality has been reduced in acute coronary syndromes, the latter will be the main condition resulting in CHF. This concept stimulated a systematic, quantitative study in 144 hearts with irreversible insufficiency excised at transplantation compared with 144 hearts without CHF both from patients and normal subjects dead from accident [1]. The aim of this review is to discuss a consensus on CHF which, independently of the underlying disease, is considered: "secondary to absolute or relative ischemia, remodelling of heart shape by enlarged volume, increased mass, cardiac wall thinning, lengthening of cardiomyocytes, continuous infarct expansion, scar formation, apoptosis, hypertrophy, slippage of myocardial cells and increased interstitial fibrosis, and neurohormonal activation" [2]. Our 144 patients with irreversible CHF included 63 with chronic coronary heart disease, 63 with dilated cardiomyopathy and 18 with chronic valvular heart disease. All had a similar clinical pattern. The advantage is that surgically excised hearts are free of any change which may occur in the terminal, agonic phase and interfere with other autoptic findings. The main data supporting this review are synthesize in Table 1 and main items in the consensus to be discussed are:
1. Myocardial fibrosis This variable assumes a central pathogenic meaning since it results (ischemia → continuous infarct expansion → scar) in fibrous, non contracting myocardium ending in progressive insufficiency. In all the three conditions examined, the extent of myocardial fibrosis (Figure (Figure1)1
2. Lymphocytic infiltration In dilated cardiomyopathy the etiopathogenetic hypothesis is that a chronic virus myocarditis resulting in myocardial fibrosis explains this pathologic condition. Both myocardial fibrosis, as already mentioned, and lymphocytic infiltrates, as expression of a virus infection, showed a too low frequency and extent. In particular the number of lymphocytic foci was less than controls in all the insufficient hearts, with a number of elements per focus less than 20. Only in "silent" Chagas patients [apparently healthy subjects serum-positive for this disease who died suddenly and unexpectedly] an extensive lymphocytic myocarditis associated with catecholamine necrosis was observed. 3. Ischemia A clinical study has shown that ischemic episodes are not part of CHF [4]. On the other hand, in coronary artery disease + CHF group an acute, silent infarct was detected in five of 63 hearts, transmural in two and subendocardial in three with a histological age between 20–30 days. In controls, one Chagas patient had a ten day old anterior infarct and four AIDS subjects, all with normal coronary arteries had a microfocal, four day old infarct in the anterior papillary muscle. If ischemia is the cause of CHF we should have a higher frequency of infarct necrosis. 4. Apoptosis This genomically programmed cell death, supposed to be triggered by many risk factors, has been recently advocated to explain different cardiac pathologies in which apoptosis has been indirectly "demonstrated" by TUNEL techniques [5]. This necrosis is defined as shrinkage of single cell with fragmentation of its nucleus forming "apoptotic bodies" easy to recognize within or outside the dead cell. The apoptotic cell then disappears without evidence of collagen substitution [6], a finding never observed in our human and experimental material [5]. The claim, that lost of myocardial cells by apoptosis may explain cardiac insufficiency, is contradicted by the heavy weight of insufficient hearts. Lost of myocytes should correspond to normal, if not subnormal heart weight. 5. Thinning cardiac wall/lengthening of myocytes The weight/size paradox i.e. heavy heart weight with both cardiac wall and myocyte normal thickness is explained by dilatation of heart chambers with lengthening by distension of myocardial cells resulting in normal wall thickness. Such a stretch of myocytes does not occur [1] as shown histologically and ultrastructurally (note in Figure Figure2).2
6. Hypertrophy By cardiac hypertrophy we mean a tridimensional augmentation in number of myofibrils and other components of myocardial cells to compensate an increase of heart work. The myocyte hypertrophy results in a heavy cardiac weight. When insufficiency begins the weight/size paradox can not be explained by longitudinal division of myocytes never demonstrated or by neogenesis of myocytes [8-10], a concept difficult to be accepted since the hypertrophying stimulus persists and the new elements should hypertrophy. 7. Slippage of myocytes To explain the paradox, the other well granted hypothesis is that an interpenetration of myocytes may reduce the cardiac wall thickness. First, such never proved interpenetration may explain the latter and dilatation of heart cavities (Figure (Figure2).2 8. Neurohormonal activation This assumption has a confirmation in the high frequency of catecholamine necrosis [7] even if the extent of the lesion is very small (Table 1). The first conclusion is that the pooling of all items of the quoted consensus has no support from morphopathology, but neurohormonal activation which, per se, does not explain congestive failure rather an adrenergic stress prevented by beta-blocking therapy. However, the following two findings not mentioned in this consensus are the following. 9. Colliquative myocytolysis This non ischemic lesion [7] is typical of congestive heart failure (Figure (Figure3)3
10. Endomioelastofibrosis This change is worthy of mention to avoid any confusion with embologenic endocardial thrombosis. The presence of the latter was 21% in coronary heart disease, 10% in dilated cardiomyopathy and 6% of valvulopathic patients with CHF. Most of these endocardial thrombi were organized. Myoelastofibrosis was demonstrated in 98% of congestive hearts being present also in controls (Table 2). It starts as smooth muscle cell nodular proliferation below the normal endothelial cells of the endocardium (Figure (Figure4),4
Target of Ultrasound Diagnosis: Present and Future Though various imaging techniques have been introduced for assessing left ventricular function, echocardiography still represents the main choice in the clinical arena due to its unique combination of safety, feasibility, and reliability (Table 3). Both diastolic and systolic function of the heart can be easily explored by echocardiography.
1. Diastolic function Doppler echocardiography traditionally allows diastolic abnormalities affecting overall cardiac function to be easily detected on routine examination. Inversion of the E/A ratio and prolongation of deceleration time on the transmitral flow pattern represent the first abnormalities which are encountered in the minor stage of diastolic dysfunction. A restrictive filling pattern, reflecting an increased pulmonary capillary pressure, is observed in case of more severe dysfunction and is associated to adverse outcome [11]. More recently, Tissue Doppler Imaging (TDI) has provided robust, relatively unambiguous, well validated tool that is more reliable than the use of pulmonary vein Doppler, flow propagation velocity or load altering techniques [12]. The clinical role of echocardiography for evaluating diastolic function is quite different depending on whether global left ventricular (LV) systolic function is preserved or not. In patients with preserved systolic function, measurement of transmitral flow in combination with mitral annular tissue Doppler velocities provide the most efficient means of assessing LV diastolic function and filling pressures. However, in case of global systolic dysfunction and accompanying diastolic dysfunction, the principal aim of Doppler echocardiography is to estimate filling pressure, which has known therapeutic and prognostic implications [13]. In these patients, diastolic Doppler parameters are principally used to determine LV filling pressures [13]. Finally, when the regional assessment of the diastolic function is the target, TDI presently represents the best echocardiographic approach. 2. Systolic function Initially described in studies including contrast or radionuclide ventriculography, global and regional left ventricular function are optimally assessed with echocardiographic technique in both resting and stress condition. With the ultrasound beam directed perpendicularly to the myocardium, wall motion and thickening can easily be detected on the imaging plane. Several imaging windows, including parasternal, apical, and subcostal views, are used to visualize all ventricular walls. More recently, three dimensional (3D) echocardiographic images are generated by integration of information from multiple 2D imaging planes. In addition, the introduction of harmonic imaging and the use of echocardiographic contrast media for improved endocardial border definition have significantly improved image quality, thereby enhancing the accuracy of assessment of left ventricular function particularly in patients with poor acoustic windows. Estimation of the LVEF by 2D echocardiography can be done either qualitatively by visual inspection of global and regional function or quantitatively, using geometric assumptions regarding the shape of the LV cavity. Global and regional LV systolic function can both be qualitatively and quantitatively assessed with echocardiography. Global function is qualitatively described as normal, depressed, or hyperdynamic. Although a comprehensive quantitative assessment of LV end-systolic and end-diastolic data would be ideal, such an approach is currently impractical for routine evaluation. Several quantitative approaches have been described, with Simpson's rule (disk-area method) being the most accurate for LV volume measurement and for computation of derived values such as LV ejection fraction [14]. Perhaps this assessment may be obtained in the future with further development of 3D techniques and improved automated edge-detection algorithms. The regional assessment of LV systolic function is assessed by dividing the entire left ventricle into segments. The most popular models recommend the use of 16 or 17 segments [15,16]. A score is then assigned to each segment: (1 = normal, 2 = hypokinesis, 3 = akinesis, 4 = dyskinesis) and a semiquantitative wall motion score index is derived as the ratio between the sum of scores assigned to each segment and the number of visualized segments. Future developments for the assessment of ventricular function with echocardiography include the use of 3D technique and myocardial strain imaging. 3D echocardiography offers the theoretical advantage to provide incremental benefit over 2D techniques in terms of accuracy and reproducibility and appears to produce estimation of LV ejection fraction similar to radionuclide ventriculography and cardiovascular magnetic resonance [17-21]. The term "strain" refers to an object's fractional or percentage change from its original dimension [22,23], thus reflecting the deformation of a structure. When applied to the myocardium, strain directly describes the contraction/relaxation pattern and can be calculated in several dimensions [23]. Strain rate represents the rate of this deformation [22]. Strain rate imaging involves mathematical subtraction of the whole heart or translational motion from regional thickening velocity using a transmural data set from color-coded tissue Doppler echo [24,25]. This quantification of the spatial distribution of intramural velocities across the myocardium has improved the ability of tissue Doppler echo to reflect directional and incremental alterations in regional and global left ventricular contractility in patients with cardiovascular disease [24-27]. Though very promising for assessing several aspect of myocardial function, strain and strain rate imaging presently are of limited applicability in clinical practice due to several limitations [23], such as complex methodology, technical challenges of image acquisition, susceptibility to artefact and lack of standardization. Conclusion The cause of CHF is still unknown, with the impression, based on morphopathologic data, that its pathogenesis consists in a primary metabolic error of myocytes which lost their ability to relax in the contraction cycle. At ultrastructure these elements are in contraction and this finding may indicate the inability to remove Ca+2 from troponin-tropomyosine complex. The metabolic error could stimulate an abortive hypertrophy with elongation of myocytes by new sarcomeres with normal length without tridimensional myofibrillar iperplasia [1,4]. Competing interests The author(s) declare that they have no competing interests. Authors' contributions GB conceived and drafted the manuscript. RG and LC critically revised and helped to draft the manuscript. All authors read and approved the final manuscript. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
J Am Coll Cardiol. 2000 Mar 1; 35(3):569-82.
[J Am Coll Cardiol. 2000]Can J Cardiol. 1997 Jan; 13(1):65-71.
[Can J Cardiol. 1997]J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):22A-29A.
[J Am Coll Cardiol. 1993]Am J Pathol. 1995 Jan; 146(1):3-15.
[Am J Pathol. 1995]Am Heart J. 1993 Feb; 125(2 Pt 1):410-22.
[Am Heart J. 1993]J Mol Cell Cardiol. 1997 Oct; 29(10):2789-802.
[J Mol Cell Cardiol. 1997]Cardiovasc Ultrasound. 2005 Oct 6; 3():32.
[Cardiovasc Ultrasound. 2005]Am Heart J. 1993 Feb; 125(2 Pt 1):410-22.
[Am Heart J. 1993]Am Heart J. 1993 Feb; 125(2 Pt 1):410-22.
[Am Heart J. 1993]Eur Heart J. 1988 Jun; 9(6):649-56.
[Eur Heart J. 1988]Circulation. 2000 Oct 10; 102(15):1788-94.
[Circulation. 2000]Heart. 2005 May; 91(5):681-95.
[Heart. 2005]Circulation. 1979 Oct; 60(4):760-6.
[Circulation. 1979]J Am Soc Echocardiogr. 1989 Sep-Oct; 2(5):358-67.
[J Am Soc Echocardiogr. 1989]Circulation. 2002 Jan 29; 105(4):539-42.
[Circulation. 2002]Circulation. 1995 Aug 15; 92(4):842-53.
[Circulation. 1995]J Am Coll Cardiol. 2004 Jun 2; 43(11):2083-90.
[J Am Coll Cardiol. 2004]J Am Coll Cardiol. 2001 Mar 1; 37(3):731-4.
[J Am Coll Cardiol. 2001]J Am Coll Cardiol. 2006 Apr 4; 47(7):1313-27.
[J Am Coll Cardiol. 2006]J Am Soc Echocardiogr. 2004 Jul; 17(7):788-802.
[J Am Soc Echocardiogr. 2004]J Am Coll Cardiol. 1995 Jul; 26(1):217-23.
[J Am Coll Cardiol. 1995]J Am Coll Cardiol. 2001 Mar 1; 37(3):726-30.
[J Am Coll Cardiol. 2001]J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):22A-29A.
[J Am Coll Cardiol. 1993]